Clinical trials: Metastasis Colorectal Cancer
Explore the Consistency of Drug Sensitivity Between Primary Colorectal Cancer and Liver Metastases
Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis
Accumulating evidence indicates that patient- derived organoids (PDOs) can predict drug responses in the clinic. Metastasis is the main cause of death in colorectal cancer patients, and the treatment of patients with liver…
- Trial name
- NCT05183425
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC)
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab.
- Conditions
- Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
- Trial name
- NCT06784947
- Testing
- Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Refractory Metastatic Colorectal Cancer
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and…
- Trial name
- DEL-LIVER (NCT06607458)
- Testing
- Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
- Where
- 20 sites in United States, Czechia and 7 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
Colorectal Cancer
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of Ro 31-7453 in…
- Trial name
- NCT00016250
- Testing
- MKC-1
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Colorectal Cancer
NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have metastatic or…
- Trial name
- NCT00031616
- Testing
- brivudine phosphoramidate
- Where
- 2 sites in United States
- Sponsor
- NewBiotics
Gastrointestinal Cancer
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow.
- Trial name
- NCT01058655
- Testing
- Everolimus, Tivozanib
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Colorectal Cancer
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab plus cetuximab and chemotherapy for patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer.
- Trial name
- NCT06231017
- Testing
- Adebrelimab + Cetuximab+ Chemotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Colorectal Cancer Metastatic
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC.
- Trial name
- EORTC1615 (NCT03470350)
- Testing
- Galunisertib
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer, Liver Metastases
Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
To evaluate whether a combination regimen of pentoxifylline, ursodeoxycholic acid and enoxaparin provides a protective effect on the liver parenchyma after high dose rate (HDR) brachytherapy.
- Conditions
- Colorectal Cancer, Liver Metastases, Irradiation Damage, Radiation Induced Liver Disease
- Trial name
- ELDORADO (NCT01149304)
- Testing
- Pentoxifylline, Ursodeoxycholic Acid, Enoxaparin
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- University of Magdeburg
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Background: Metastatic colorectal cancer (mCRC) is cancer that has spread beyond the colon and rectum. Most people with mCRC die within 5 years. New immune-based treatments are making progress with some types of colon cancer.
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
- Trial name
- NCT06603818
- Testing
- Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer With Liver Metastasis
Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis
Objective: To evaluate the role of regional lymphadenectomy in patients with colorectal cancer liver metastasis. Background: Lymph node status is 1 of the most important prognostic factors in oncologic surgery; however, the role…
- Trial name
- LN (NCT01565811)
- Testing
- perihepatic lymphadenectomy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Gachon University Gil Medical Center
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Colorectal Cancer, Liver Metastases
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal…
- Conditions
- Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related
- Trial name
- NCT05797077
- Testing
- Colorectal resection surgery., FOLFOX chemotherapy regimen, Capecitabine
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Advanced/Metastatic Colorectal Adenocarcinoma
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS.
- Trial name
- NCT07535112
- Testing
- BAY 3771249, Cetuximab
- Where
- 21 sites in United States, Australia and 8 more
- Volunteers
- 130 people
- Sponsor
- Bayer
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Metastatic Colorectal Cancer
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00459901
- Testing
- Erlotinib and capecitabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Peter Kozuch
Metastatic Colorectal Cancer
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
To explore the safety, efficacy and pharmacokinetic (PK) characteristics of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: a…
- Trial name
- NCT05775900
- Testing
- Cetuximab, Capecitabine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
The morbidity of colorectal cancer(CRC) is 10%～15% in China.mFolfox6 has become one of the standard regimes for metastatic colorectal cancer (mCRC).
- Trial name
- NCT02024412
- Testing
- monosialotetrahexosylganglioside Sodium
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Circulating Tumor Cell
Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery
To compare the effects of three types of perioperative analgesia on the number of circulating tumor cells following radical colorectal cancer surgery.
- Trial name
- POACC-1 (NCT03700411)
- Testing
- Morphine, Piritramid, Epidural
- Where
- 3 sites in Czechia
- Volunteers
- 125 people
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.